Clinical Trial

Type 1 Diabetes, Endothelin, and Skeletal Muscle Mitochondrial Dysfunction: The Role of Sirtuin-1

Study acronym: T-St1M
Recruiting Early Phase 1
View on ClinicalTrials.gov →
Summary
The proposed study is designed to test the hypothesis that treatment of resveratrol for 12 weeks will improve both endothelin-B receptor (aim 1) and skeletal muscle mitochondrial function (aim 2) in people with type 1 diabetes.
Protocol Amendment History 5 amendments
This ClinicalTrials.gov record has been amended 5 times since 2020-06-23; most recent amendment 2025-01-27.
Status change: Not Yet Recruiting → Recruiting 2021-01-15
Trial Details
NCT Number NCT04449198
Lead Sponsor Augusta University
Conditions Type 1 Diabetes
Enrollment 24 participants
Start Date 2020-10-14
Primary Completion 2027-01-01 (estimated)
Study Completion 2027-07-01 (estimated)
Updated on ClinicalTrials.gov 2025-01-28